Department of Defense Requests Permission to Use Encision Images

Jun 09, 2010, 13:35 ET from Encision Inc.

BOULDER, Colo., June 9 /PRNewswire-FirstCall/ -- Encision Inc. (OTC Bulletin Board: ECIA), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, granted permission to the Department of Defense's ("DOD") Patient Safety Analysis Center to use images from Encision's web site pertaining to insulation failure and capacitive coupling.

"We are pleased to contribute to the DoD's Patient Safety Analysis Center's effort to increase the awareness of the potential complications during laparoscopy surgery," said Jack Serino, President and CEO of Encision Inc. "While laparoscopic surgery is, generally, a safe procedure and widely used for common procedures like gallbladder removal, there are still risks associated with electrosurgery, including stray energy burns from laparoscopic instrument insulation leakage and capacitive coupling."

Encision's AEM® automatic sensing technology was developed to address the prevention of stray energy burns to patients from insulation failure and capacitive coupling during laparoscopic surgery.  Our active electrode monitoring continuously monitors and drains excess capacitively coupled current from our coaxially shielded laparoscopic instruments during surgery. Also, it safely diverts radiofrequency current in the event that a breach to our instrument occurs during surgery and shuts off the electrosurgical generator, thereby protecting the patient from burns due to insulation failure.

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in our filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT:  Marcia McHaffie, Encision Inc., 303-444-2600,

SOURCE Encision Inc.